John F. Heerdink, Jr. on LinkedIn: #nashville #tennessee #artificialintelligence #ai #machinelearning #ceo… (2024)

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage #biotechnology company leveraging its proprietary #DiffuSphere™ #technology to #optimize #drugdelivery for applications with significant unmet need, today announced that results from its Phase 2 study of EP-104IAR for the treatment of #osteoarthritis of the #knee will be presented at the upcoming European Alliance of Associations for Rheumatology #EULAR European Congress of #Rheumatology 2024. The EULAR Meeting is being held in #Vienna, #Austria from June 12-15, 2024.

"Intel Corp. $INTC agreed to sell a stake in a #venture that controls a plant in #Ireland to Apollo Global Management Inc. for $11 billion." $DIA $SPY $QQQ $LTRN

1

"US stocks nudged higher before the bell on Wednesday, buoyed by tentative #optimism for #interestrate cuts amid signs of slowing labor demand and a cooling #economy." $SPY $QQQ $DIA #Wednesday

"Job openings fell in April to their lowest level since February 2021 as the labor market shows further signs of cooling off from the hiring boom that followed the US economy reopening after the pandemic.New data from the Bureau of Labor Statistics released Tuesday showed there were 8.06 million jobs open at the end of April, a decrease from the 8.35 million job openings in March" $SPY $DIA $QQQ

Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage #biotechnology company dedicated to pioneering innovative #cancer and #viralinfection treatments, today announced that its CMO #RogerWaltzman, M.D., will present an update on the Company’s lead product candidate, Decoy20, at the 7th Annual #NextGen Immuno-Oncology Conference in #Boston on June 20-21, 2024. https://lnkd.in/gzCw6hVWRoger Waltzman, M.D., M.B.A. currently serves as Chief Medical Officer. Dr. Waltzman is a board-certified medical #oncologist whose career highlights include the roll of Chief Medical Officer of publicly traded company, Molecular Templates (2019-2023) and multiple senior drug development roles at #Novartis Oncology (2007–2013), where he played a leading role in the development of imatinib, nilotinib, and ruxolitinib. From 2013 to 2016, Dr. Waltzman was the Full Development Head of #Malaria Drug Development at Novartis. More recently, Dr. Waltzman was CMO at Rgenix (now #Inspirna), where he supervised the development of immuno-oncology and metabolic inhibitor assets through Phase 1 a/b. Previously, he served as CSO at Jaguar Health and Napo Pharmaceuticals, where he led scientific aspects of development and commercialization of Mytesi® (crofelemer).Before joining the industry, Dr. Waltzman held assistant professorships in medical oncology and palliative care at Saint Vincent’s Hospital and #MountSinai School of Medicine in #NewYork. He completed his fellowship in hematology/oncology at #MemorialSloanKettering Cancer Center. Dr. Waltzman earned a Master of Business Administration at #ColumbiaBusinessSchool and a Doctor of Medicine and Bachelor of Arts from #BrownUniversity.#Massachusetts #healthcare #medical

2

"Nvidia $NVDA shares are about to get a whole lot cheaper, and, no, that's not some bold prognostication for the world’s hottest stock: the #artificialintelligence semiconductor chip designer is on the cusp of executing a stock split announced last month."$LTRN